U.S. markets open in 9 hours 1 minute

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
71.28-1.32 (-1.82%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close72.60
Bid71.31 x 1100
Ask71.49 x 1800
Day's Range70.82 - 79.30
52 Week Range13.00 - 126.90
Avg. Volume1,166,679
Market Cap4.164B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.83
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est102.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

    Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

    CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021 Global Healthcare Conference on Thursday, March 11, 2021 at 2:25 p.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com. Contacts: Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com Media:Dan Budwick1ABdan@1abmedia.com

  • Beam Therapeutics Dives On $120 Million Takeover Of Guide Therapeutics
    Investor's Business Daily

    Beam Therapeutics Dives On $120 Million Takeover Of Guide Therapeutics

    Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. Broadly, biotech stocks were under pressure.

  • Benzinga

    Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

    Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million more in milestone payments. Beam is betting that adding GuideTx’s lipid nanoparticle (LNP) drug delivery vehicles to the mix will boost its genetic medicines’ reach into new tissues and disease areas. GuideTx’s LNP screening technology tags nanoparticles with DNA barcodes allows hundreds of nanoparticles to be screened in one experiment, in a single animal. So far, GuideTx has identified a library of lipids and lipid formulations that could ramp up the development of gene editing treatments to tissues other than the liver. Price Action: BEAM is down 14.4% at $94.56 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaProgenity Secures M Via Equity Issued At 5% DiscountAkers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.